191 related articles for article (PubMed ID: 29395577)
1. HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors.
Fujii K; Suzuki N; Jimura N; Idogawa M; Kondo T; Iwatsuki K; Kanekura T
J Dermatol Sci; 2018 Apr; 90(1):82-89. PubMed ID: 29395577
[TBL] [Abstract][Full Text] [Related]
2. Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.
Fujii K; Idogawa M; Suzuki N; Iwatsuki K; Kanekura T
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681913
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation.
Mawatari T; Ninomiya I; Inokuchi M; Harada S; Hayashi H; Oyama K; Makino I; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
Int J Oncol; 2015 Dec; 47(6):2073-81. PubMed ID: 26497673
[TBL] [Abstract][Full Text] [Related]
4. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
5. Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
Hajji N; Wallenborg K; Vlachos P; Füllgrabe J; Hermanson O; Joseph B
Oncogene; 2010 Apr; 29(15):2192-204. PubMed ID: 20118981
[TBL] [Abstract][Full Text] [Related]
6. Proteomic study identified HSP 70 kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms.
Fujii K; Suzuki N; Ikeda K; Hamada T; Yamamoto T; Kondo T; Iwatsuki K
J Proteomics; 2012 Feb; 75(4):1401-10. PubMed ID: 22123078
[TBL] [Abstract][Full Text] [Related]
7. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.
Falkenberg KJ; Newbold A; Gould CM; Luu J; Trapani JA; Matthews GM; Simpson KJ; Johnstone RW
Cell Death Differ; 2016 Jul; 23(7):1209-18. PubMed ID: 26868908
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
[TBL] [Abstract][Full Text] [Related]
10. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
[TBL] [Abstract][Full Text] [Related]
13. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
14. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation.
Zhang Z; Qin X; Tong N; Zhao X; Gong Y; Shi Y; Wu X
Exp Eye Res; 2012 Jan; 94(1):98-108. PubMed ID: 22143029
[TBL] [Abstract][Full Text] [Related]
16. TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cells.
Cao QF; Qian SB; Wang N; Zhang L; Wang WM; Shen HB
Cancer Biother Radiopharm; 2015 Mar; 30(2):87-93. PubMed ID: 25760728
[TBL] [Abstract][Full Text] [Related]
17. Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors.
Halsall J; Gupta V; O'Neill LP; Turner BM; Nightingale KP
PLoS One; 2012; 7(3):e33453. PubMed ID: 22479401
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
19. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
Chang YL; Huang LC; Chen YC; Wang YW; Hueng DY; Huang SM
Int J Biochem Cell Biol; 2017 Nov; 92():155-163. PubMed ID: 29017950
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni.
Dubois F; Caby S; Oger F; Cosseau C; Capron M; Grunau C; Dissous C; Pierce RJ
Mol Biochem Parasitol; 2009 Nov; 168(1):7-15. PubMed ID: 19538992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
